Recombinant Mouse SF-20/IL-25

Description :
FAQ COA 已发表文献 SF-20, or MYDGF, is a Bone marrow-derived monocyte protein, and it is correlated with enhanced metabolic activity, suppression of apoptosis, and stimulation of cell proliferation. MYDGF is expressed predominantly in inflammatory cells, such as monocytes and macrophages. Up-regulation of MYDGF expression was also found during adipocyte differentiation. Expression of MYDGF was induced in the circulation and heart tissue after myocardial infarction. It promotes cardiac myocyte survival by stimulating endothelial cell proliferation through a MAPK1/3-, STAT3- and CCND1-mediated signaling pathway, and inhibits cardiac myocyte apoptosis in a PI3K/AKT-dependent signaling pathway. MYDGF was found over-expressed in approximately two-thirds of Hepatocellular Carcinoma (HCC) tissues, and its expression was significantly positively correlated with that of alpha-fetoprotein (AFP). In HCC, MYDGF could regulate cell proliferation through activating Akt/mitogen-activated protein kinase pathways. Mouse MYDGF shares 92% amino acid sequence identity with both human and rat MYDGF. Intriguingly, virtually all homologs of MYDGF have a C-terminal putative ER retention sequence BXEL (B: Arg, His, or Lys; X: variable residue; E: Glu; L: Leu), which has the potential to retain human MYDGF and its homologs in the ER, whereas truncated MYDGF without BXEL is secreted from the cell. However, the functions of these different forms remain unclear. Product Properties Synonyms IL-17E, IL-25, MYDGF Accession Q9CPT4 GeneID 28106 Source E.coli-derivedMouse SF-20/IL-25, Val25-Leu166, with an N-terminal Met. Molecular Weight Approximately 15.8 kDa. AA Sequence MVSEPTTVPF DVRPGGVVHS FSQDVGPGNK FTCTFTYASQ GGTNEQWQMS LGTSEDSQHF TCTIWRPQGK SYLYFTQFKA ELRGAEIEYA MAYSKAAFER ESDVPLKSEE FEVTKTAVSH RPGAFKAELS KLVIVAKAAR SEL Tag None Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Purity > 95% by SDS-PAGE and HPLC analyses. Biological Activity Data Not Available. Endotoxin 1.0EU per 1g of the protein by the LAL method. Formulation Lyophilized from a 0.2 m filtered concentrated solution in PBS, pH 7.4. Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20C. Further dilutions should be made in appropriate buffered solutions.